Medtronic shares close at $102.88 as Hugo clearance for general surgery remains uncertain
Key Facts
Medtronic shares closed at $102.88 in the November 16, 2026 session, according to EL7 data. The close came as U.S. Food and Drug Administration clearance for the Hugo system’s use in general surgery remained unconfirmed, the focus of a news report circulating on November 17. Medtronic announced on June 3 that it had filed a 510(k) submission to expand the system’s use to general surgery, including hernia repair. That earlier step establishes that the company sought to broaden the system’s use, but does not itself constitute a regulatory approval decision. The available FDA record for the system concerns an earlier decision and does not establish that subsequent clearance for general surgery was issued.
The FDA record is numbered K250725 and lists a decision dated December 3, 2025, finding substantial equivalence. That decision concerns the submission on file at that time; it does not by itself confirm the outcome of the expansion application Medtronic announced later. In its June statement, the company included general surgery, including hernia repair, among the uses it had applied to add. Medtronic estimated that around 470,000 ventral hernia repair procedures are performed annually in the United States. The figure puts the scale of one of the procedures cited by the company in the context of its application, without meaning the system has been cleared for use in those procedures.
Medtronic said in June that the Hugo system was in commercial use in more than 35 countries across 5 continents. It added that the system had been used in tens of thousands of procedures and that hundreds of independently published scientific papers supported its safety and effectiveness, according to the company. In February 2026, the company announced the first U.S. commercial surgical case using Hugo at Cleveland Clinic. The procedure was a robot-assisted prostatectomy, and the patient left the hospital the following day. These facts form part of the usage record the company cited before its June announcement of an application to expand use in the United States.
On the regulatory timeline, MedTech Dive reported in June that Medtronic had not then provided a timeline for clearance for the new uses. The outlet quoted the chief executive as saying the two applications were filed in late April 2026. It also reported that U.S. surgeons used da Vinci systems in about 2 million procedures in the year before its report, based on data from Intuitive Surgical. General surgery accounted for 1.25 million of those procedures, according to the same report. These figures provide a comparison for the scale of use in the robotic surgery market, while Medtronic’s November 16 close at $102.88 remains the latest market figure in the available information.